Personalis (NASDAQ:PSNL) and Centogene (NASDAQ:CNTG) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, profitability, earnings, analyst recommendations, valuation, institutional ownership and risk.
This is a breakdown of recent ratings and price targets for Personalis and Centogene, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Personalis presently has a consensus price target of $22.25, suggesting a potential upside of 74.65%. Centogene has a consensus price target of $21.50, suggesting a potential upside of 9.64%. Given Personalis’ higher probable upside, research analysts plainly believe Personalis is more favorable than Centogene.
This table compares Personalis and Centogene’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Institutional & Insider Ownership
60.9% of Personalis shares are held by institutional investors. Comparatively, 8.4% of Centogene shares are held by institutional investors. 8.2% of Personalis shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Earnings and Valuation
This table compares Personalis and Centogene’s top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Personalis||$65.21 million||6.20||-$25.08 million||($1.39)||-9.17|
|Centogene||$54.64 million||7.13||-$23.36 million||($1.46)||-13.43|
Centogene has lower revenue, but higher earnings than Personalis. Centogene is trading at a lower price-to-earnings ratio than Personalis, indicating that it is currently the more affordable of the two stocks.
Personalis beats Centogene on 7 of the 12 factors compared between the two stocks.
Personalis, Inc. operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies. It offers NeXT platform, a clinical-grade, next generation sequencing and analysis platform that enables the development of ImmunoID NeXT tumor biopsy and liquid biopsy, as well as provides analysis of tumor and immune microenvironment from a single limited tissue sample, tumor molecular profiling for cancer patients, and anticipates future cancer biomarkers. The company also provides accuracy and content enhanced platform (ACE) that enhances nucleic acid preparation processes and combines it with patented assay and sequencing methods. ACE Platform offers multiple products and services, such as ACE extended cancer panel for DNA and RNA, and ACE cancer research Exome and Transcriptome. In addition, it develops NeXT Dx test, which helps oncologists to identify potential therapies and clinical trial options for cancer patients, as well as offers whole genome sequencing, which provides DNA sequencing and data analysis services; and ACE CancerPlus Test. The company also provides a liquid biopsy assay that analyzes various human genes versus the more narrowly focused liquid biopsy assays that are currently available. It serves approximately 50 biopharmaceutical customers, including a range of pharmaceutical companies. The company was founded in 2011 and is headquartered in Menlo Park, California.
Centogene B.V. operates as a commercial-stage rare disease company worldwide. It focuses on transforming clinical and genetic data into medical solutions for patients, physicians, and pharmaceutical companies. The company develops rare disease platform, a data repository, which includes epidemiologic, phenotypic, and heterogenetic data that enhances methods for identifying and monitoring rare hereditary diseases and provide solutions that accelerate the development of orphan drugs. It operates through two segments, Pharmaceutical and Diagnostics. The Pharmaceutical segment offers various services, including early patient recruitment and identification, epidemiological insights, biomarker discovery, and patient monitoring. The Diagnostics segment provides genetic sequencing and diagnostics services to physicians, laboratories, or hospitals directly or through distributors. Centogene B.V. was founded in 2006 and is headquartered in Rostock, Germany.
Receive News & Ratings for Personalis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Personalis and related companies with MarketBeat.com's FREE daily email newsletter.